Page 156 - Haematologica April 2020
P. 156

L. Boutin et al.
action. Biochem Biophys Res Commun.
2007;363(3):578–583.
30. Boyd AL, Aslostovar L, Reid J, et al.
Identification of Chemotherapy-Induced Leukemic-Regenerating Cells Reveals a Transient Vulnerability of Human AML Recurrence. Cancer Cell. 2018;34(3):483- 498.e5.
31. Moschoi R, Imbert V, Nebout M, et al. Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemothera- py. Blood. 2016;128(2):253–264.
32. Saygin C, Matei D, Majeti R, Reizes O, Lathia JD. Targeting Cancer Stemness in the Clinic: From Hype to Hope. Cell Stem Cell. 2019;24(1):25–40.
33. Varatharajan S, Abraham A, Karathedath S, et al. ATP-binding casette transporter
expression in acute myeloid leukemia: association with in vitro cytotoxicity and prognostic markers. Pharmacogenomics. 2017;18(3):235–244.
34. Kolitz JE, George SL, Marcucci G, et al. P- glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010;116(9):1413–1421.
35. Cripe LD, Uno H, Paietta EM, et al. Zosuquidar, a novel modulator of P-glyco- protein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo- controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010;116(20):4077–4085.
36. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res. 2001;42(7):1007– 1017.
37. Sawicki E, Schellens JHM, Beijnen JH, Nuijen B. Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-con- cept clinical studies. Drug Dev Ind Pharm. 2017;43(4):584–594.
38. Robey RW, Pluchino KM, Hall MD, Fojo AT, Bates SE, Gottesman MM. Revisiting the role of ABC transporters in multidrug- resistant cancer. Nat Rev Cancer. 2018;18(7):452-464.
39. Wijaya J, Fukuda Y, Schuetz JD. Obstacles to Brain Tumor Therapy: Key ABC Transporters. Int J Mol Sci. 2017;18(12).
998
haematologica | 2020; 105(4)


































































































   154   155   156   157   158